ClinicalTrials.gg
CompletedNCT02760498Updated May 28, 2025Results posted

Study of REGN2810 in Patients With Advanced Cutaneous Squamous Cell Carcinoma

A Phase 2 interventional study of cemiplimab in Advanced Cutaneous Squamous Cell Carcinoma, sponsored by Regeneron Pharmaceuticals. Completed at 78 sites in 8 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-05-28.

Sponsored by Regeneron Pharmaceuticals · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
432
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Study summary

The goals of this study are to evaluate the clinical benefit and safety of cemiplimab in participants with metastatic (nodal or distant) Cutaneous Squamous Cell Carcinoma (CSCC), or unresectable locally advanced CSCC.

02

Conditions studied

  • Advanced Cutaneous Squamous Cell Carcinoma

Keywords

  • Metastatic CSCC
  • Unresectable locally advanced CSCC
03

In context

Lead sponsor

Regeneron Pharmaceuticals is the lead sponsor of 412 studies on the registry; 90 are open to participants now.

Of its 126 completed or terminated interventional studies of FDA-regulated products, 79 (63%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  • At least 1
  • (ECOG) performance status ≤1
  • Adequate bone marrow function
  • Adequate renal function
  • Adequate hepatic function
  • Archived or newly obtained tumor material
  • Patients must consent to undergo of CSCC lesions (Groups 2, 4, and 6)
  • Surgical or radiological treatment of lesions

Key Exclusion Criteria:

  • Ongoing or recent (within 5 years) evidence of significant disease that required treatment with systemic treatments, which may suggest risk for immune-related adverse events
  • Prior treatment with an agent that blocks the /PD-L1pathway
  • Prior treatment with a BRAF inhibitor
  • Prior treatment with other immune-modulating agents within fewer than 4 weeks prior to the first dose of cemiplimab, or associated with immune-mediated adverse events that were ≥ grade 1 within 90 days prior to the first dose of cemiplimab, or associated with toxicity that resulted in discontinuation of the immune-modulating agent. Examples of immune-modulating agents include therapeutic vaccines, cytokine treatments, or agents that target cytotoxic T-lymphocyte antigen 4 (CTLA-4), 4-1BB (CD137), or OX-40.
  • Untreated (es) that may be considered active
  • Immunosuppressive doses (>10 mg prednisone daily or equivalent) within 4 weeks prior to the first dose of cemiplimab
  • Infection with (HIV) and/or chronic/active infection with virus or virus
  • History of non-infectious pneumonitis within the last 5 years
  • Allergic reactions or acute reaction attributed to antibody treatments
  • Known allergy to doxycycline or tetracycline
  • Patients with a history of solid organ transplant
  • Any medical co-morbidity, physical examination finding, or metabolic dysfunction, or clinical laboratory abnormality that renders the patient unsuitable

Other protocol-defined inclusion/exclusion criteria apply

Terms in these criteria, in plain language(13)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
432 participants (actual)

Study arms

  • Experimental
    Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg Q2W

    Participants received cemiplimab 3 milligrams (mg)/kilogram (kg) intravenously (IV) every 2 weeks (Q2W) during each 8-week treatment cycle, for up to 96 weeks (12 cycles).

    Drug: cemiplimab

  • Experimental
    Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg Q2W

    Participants received cemiplimab 3 mg/kg IV Q2W during each 8-week treatment cycle, for up to 96 weeks (12 cycles).

    Drug: cemiplimab

  • Experimental
    Group 3 (Participants With mCSCC): Cemiplimab 350 mg Q3W

    Participants received cemiplimab 350 mg IV every 3 weeks (Q3W) during each 9-week treatment cycle, for up to 54 weeks (6 cycles).

    Drug: cemiplimab

  • Experimental
    Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg Q4W

    Participants received cemiplimab 600 mg IV every 4 weeks (Q4W) during each 8-week treatment cycle, for up to 48 weeks (6 cycles).

    Drug: cemiplimab

  • Experimental
    Group 5 (Participants With mCSCC and laCSCC): Cemiplimab SC + 350 mg Q3W

    Participants received a single subcutaneous (SC) dose of cemiplimab followed by cemiplimab 350 mg IV Q3W during each 9-week treatment cycle, for up to 54 weeks (6 cycles).

    Drug: cemiplimab

  • Experimental
    Group 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg Q3W

    Participants received cemiplimab 350 mg IV Q3W during each 9-week treatment cycle, for up to 108 weeks (12 cycles).

    Drug: cemiplimab

Interventions

06

What researchers measure

Primary outcomes

  1. Overall Response Rate (ORR) by Independent Central Review

    ORR was defined as percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR). For participants with metastatic disease, Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 was used to determine BOR. For participants with unresectable locally advanced disease, clinical response criteria were used. RECIST v1.1 Criteria: -CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeter (mm) \<1 (centimeter (cm). -PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Clinical Response Criteria: -CR: All target and nontarget lesion(s) no longer visible, maintained for at least 4 weeks and no new lesions. -PR: Decrease of at least 50% in the sum the products of perpendicular longest dimensions of target lesion(s), maintained for at least 4 weeks and no new lesions.

    Time frame: Up to 108 weeks

Secondary outcomes

  1. ORR by Investigator Assessment

    ORR was defined as percentage of participants with BOR of CR or PR. For participants with metastatic disease, RECIST v1.1 was used to determine BOR. For participants with unresectable locally advanced disease, clinical response criteria were used. RECIST v1.1 Criteria: -CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm \<1 cm. -PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Clinical Response Criteria: -CR: All target and nontarget lesion(s) no longer visible, maintained for at least 4 weeks and no new lesions. -PR: Decrease of at least 50% in the sum the products of perpendicular longest dimensions of target lesion(s), maintained for at least 4 weeks and no new lesions.

    Time frame: Up to 108 weeks

  2. Duration of Response (DOR) by Independent Central Review

    DOR was measured from the time measurement criteria were first met for CR/PR, whichever was recorded first, until the first date of recurrent or Progressive Disease (PD) or death due to any cause in participants with BOR of CR or PR. For participants with metastatic disease, RECIST v1.1 was used to determine BOR. For participants with unresectable locally advanced disease, clinical response criteria were used. RECIST v1.1 Criteria: -PD: At least a 20% increase in the sum of the diameters of target lesions with the sum demonstrating an absolute increase of at least 5 mm (0.5 cm), or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Clinical Response Criteria: -PD: increase of ≥ 25% (WHO criteria) in the sum of the products of perpendicular longest dimensions of target lesion(s) and/or the appearance of new lesions.

    Time frame: Up to approximately 65 months (treatment period + follow-up including survival follow-up)

  3. DOR by Investigator Assessment

    DOR was measured from the time measurement criteria were first met for CR/PR, as defined in Outcome Measure 1, whichever was recorded first, until the first date of recurrent or Progressive Disease (PD) or death due to any cause in participants with BOR of CR or PR. For participants with metastatic disease, RECIST v1.1 was used to determine BOR. For participants with unresectable locally advanced disease, clinical response criteria were used. RECIST v1.1 Criteria: -PD: At least a 20% increase in the sum of the diameters of target lesions with the sum demonstrating an absolute increase of at least 5 mm (0.5 cm), or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Clinical Response Criteria: -PD: increase of ≥ 25% (World Health Organization (WHO) criteria) in the sum of the products of perpendicular longest dimensions of target lesion(s) and/or the appearance of new lesions.

    Time frame: Up to approximately 65 months (treatment period + follow-up including survival follow-up)

  4. Progression-Free Survival (PFS) by Independent Central Review

    PFS was measured from start of treatment until the first date of recurrent or PD, or death due to any cause. For participants with metastatic disease, RECIST v1.1 was used to determine PD. For participants with unresectable locally advanced disease, clinical response criteria were used. RECIST v1.1 Criteria: -PD: At least a 20% increase in the sum of the diameters of target lesions with the sum demonstrating an absolute increase of at least 5 mm (0.5 cm), or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Clinical Response Criteria: -PD: increase of ≥ 25% (WHO criteria) in the sum of the products of perpendicular longest dimensions of target lesion(s) and/or the appearance of new lesions.

    Time frame: Up to approximately 65 months (treatment period + follow-up including survival follow-up)

  5. PFS by Investigator Assessment

    PFS was measured from start of treatment until the first date of recurrent or PD, or death due to any cause. For participants with metastatic disease, RECIST v1.1 was used to determine PD. For participants with unresectable locally advanced disease, clinical response criteria were used. RECIST v1.1 Criteria: -PD: At least a 20% increase in the sum of the diameters of target lesions with the sum demonstrating an absolute increase of at least 5 mm (0.5 cm), or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Clinical Response Criteria: -PD: increase of ≥ 25% (WHO criteria) in the sum of the products of perpendicular longest dimensions of target lesion(s) and/or the appearance of new lesions.

    Time frame: Up to approximately 65 months (treatment period + follow-up including survival follow-up)

  6. Overall Survival (OS)

    OS was measured from start of treatment until death due to any cause.

    Time frame: Up to approximately 65 months (treatment period + follow-up including survival follow-up)

  7. Complete Response (CR) Rate by Independent Central Review

    CR rate was defined as percentage of participants with BOR of CR. For participants with metastatic disease, RECIST v1.1 was used to determine BOR. For participants with unresectable locally advanced disease, clinical response criteria were used. RECIST v1.1 Criteria: -CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm \<1 cm. Clinical Response Criteria: -CR: All target and nontarget lesion(s) no longer visible, maintained for at least 4 weeks and no new lesions.

    Time frame: Up to 108 weeks

  8. Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status (GHS) Score

    EORTC QLQ-C30 is a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. Items contributing to the GHS/QoL, were scored 1 ("very poor") to 7 ("excellent"). A linear transformation was applied to the raw scores so that transformed score lies between 0 to 100. A higher score indicates better global health status/functioning and a negative change from baseline indicated less improvement.

    Time frame: Baseline, Up to Cycle 12 Day 1 (Week 89)

  9. Number of Participants With Any Treatment Emergent Adverse Event (TEAE)

    An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious Adverse Events (SAEs) were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. Treatment-emergent adverse events (TEAEs) are defined as those not present at baseline or represent the exacerbation of a condition present at baseline during the on-treatment period or follow-up period. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

    Time frame: Up to 108 weeks plus 105 days (5 half-lives)

  10. Peak Concentration (Cmax) of Cemiplimab

    Time frame: Up to approximately 43 months

  11. Trough Concentration (Ctrough) of Cemiplimab

    Time frame: Up to approximately 43 months

  12. Number of Participants With Treatment-Emergent Anti-cemiplimab Antibodies

    Time frame: Up to approximately 43 months

  13. ORR by Independent Central Review for Participants With Evaluable PD-L1 Assays

    ORR was defined as percentage of participants with BOR of CR or PR. Expression level of PD-L1 was assessed in tumor biopsy samples by immunohistochemistry (IHC). -CR: All target and nontarget lesion(s) no longer visible, maintained for at least 4 weeks and no new lesions. -PR: Decrease of at least 50% in the sum the products of perpendicular longest dimensions of target lesion(s), maintained for at least 4 weeks and no new lesions.

    Time frame: Up to 108 weeks

  14. DOR by Independent Central Review for Participants With Evaluable PD-L1 Assays

    DOR was measured from the time measurement criteria are first met for CR/PR, as defined in Outcome Measure 13, whichever was recorded first, until the first date of recurrent or PD or death due to any cause in participants with BOR of CR or PR. Expression level of PD-L1 was assessed in tumor biopsy samples by IHC. -PD: increase of ≥ 25% (WHO criteria) in the sum of the products of perpendicular longest dimensions of target lesion(s) and/or the appearance of new lesions.

    Time frame: Up to approximately 65 months (treatment period + follow-up including survival follow-up)

  15. PFS by Independent Central Review for Participants With Evaluable PD-L1 Assays

    PFS was measured from time of enrollment until the first date of recurrent or progressive disease, or death due to any cause. Expression level of PD-L1 was assessed in tumor biopsy samples. -PD: increase of ≥ 25% (WHO criteria) in the sum of the products of perpendicular longest dimensions of target lesion(s) and/or the appearance of new lesions.

    Time frame: Up to approximately 65 months (treatment period + follow-up including survival follow-up)

07

Results

Posted Dec 11, 2024

Participant flow

Participant flow — Overall Study
MilestoneGroup 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2WGroup 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2WGroup 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3WGroup 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4WGroup 5 (Participants With mCSCC and laCSCC): Cemiplimab 438 mg SC + 350 mg IV Q3WGroup 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W
Started597856639167
Received at least 1 dose of study drug597856639165
Completed treatment24202227550
Completed19282224364
Not completed405034396103
Withdrew: Adverse event331106
Withdrew: Death7557023
Withdrew: Lost to follow-up000003
Withdrew: Non-compliance with study drug020000
Withdrew: Participant decision142216
Withdrew: Sponsor decision000300
Withdrew: Physician decision341402
Withdrew: Disease progression21192018455
Withdrew: Withdrawal by subject475106
Withdrew: Other than specified160310
Withdrew: Not treated000002

Outcome measures

PrimaryOverall Response Rate (ORR) by Independent Central Review

ORR was defined as percentage of participants with best overall response (BOR) of complete response (CR) or partial response (PR). For participants with metastatic disease, Response Evaluation Criteria in Solid Tumors (RECIST) version 1.1 was used to determine BOR. For participants with unresectable locally advanced disease, clinical response criteria were used. RECIST v1.1 Criteria: -CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 millimeter (mm) \<1 (centimeter (cm). -PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Clinical Response Criteria: -CR: All target and nontarget lesion(s) no longer visible, maintained for at least 4 weeks and no new lesions. -PR: Decrease of at least 50% in the sum the products of perpendicular longest dimensions of target lesion(s), maintained for at least 4 weeks and no new lesions.

Time frame:
Up to 108 weeks
Reported as:
Number · percentage of participants
Overall Response Rate (ORR) by Independent Central Review
percentage of participantsGroup 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2WGroup 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2WGroup 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3WGroup 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4WGroup 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W
Overall Response Rate (ORR) by Independent Central Review50.8 (37.5 to 64.1)44.9 (33.6 to 56.6)46.4 (33.0 to 60.3)61.9 (48.8 to 73.9)47.3 (39.5 to 55.2)
SecondaryORR by Investigator Assessment

ORR was defined as percentage of participants with BOR of CR or PR. For participants with metastatic disease, RECIST v1.1 was used to determine BOR. For participants with unresectable locally advanced disease, clinical response criteria were used. RECIST v1.1 Criteria: -CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm \<1 cm. -PR: At least a 30% decrease in the sum of the diameters of target lesions, taking as reference the baseline sum diameters. Clinical Response Criteria: -CR: All target and nontarget lesion(s) no longer visible, maintained for at least 4 weeks and no new lesions. -PR: Decrease of at least 50% in the sum the products of perpendicular longest dimensions of target lesion(s), maintained for at least 4 weeks and no new lesions.

Time frame:
Up to 108 weeks
Reported as:
Number · percentage of participants
ORR by Investigator Assessment
percentage of participantsGroup 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2WGroup 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2WGroup 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3WGroup 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4WGroup 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W
ORR by Investigator Assessment50.8 (37.5 to 64.1)56.4 (44.7 to 67.6)55.4 (41.5 to 68.7)63.5 (50.4 to 75.3)52.7 (44.8 to 60.5)
SecondaryDuration of Response (DOR) by Independent Central Review

DOR was measured from the time measurement criteria were first met for CR/PR, whichever was recorded first, until the first date of recurrent or Progressive Disease (PD) or death due to any cause in participants with BOR of CR or PR. For participants with metastatic disease, RECIST v1.1 was used to determine BOR. For participants with unresectable locally advanced disease, clinical response criteria were used. RECIST v1.1 Criteria: -PD: At least a 20% increase in the sum of the diameters of target lesions with the sum demonstrating an absolute increase of at least 5 mm (0.5 cm), or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Clinical Response Criteria: -PD: increase of ≥ 25% (WHO criteria) in the sum of the products of perpendicular longest dimensions of target lesion(s) and/or the appearance of new lesions.

Time frame:
Up to approximately 65 months (treatment period + follow-up including survival follow-up)
Reported as:
Median · months
Duration of Response (DOR) by Independent Central Review
monthsGroup 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2WGroup 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2WGroup 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3WGroup 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4WGroup 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W
Duration of Response (DOR) by Independent Central ReviewNA (20.7 to NA)41.9 (20.5 to 54.6)41.3 (40.8 to 46.3)NA (30.5 to NA)31.6 (29.5 to NA)
SecondaryDOR by Investigator Assessment

DOR was measured from the time measurement criteria were first met for CR/PR, as defined in Outcome Measure 1, whichever was recorded first, until the first date of recurrent or Progressive Disease (PD) or death due to any cause in participants with BOR of CR or PR. For participants with metastatic disease, RECIST v1.1 was used to determine BOR. For participants with unresectable locally advanced disease, clinical response criteria were used. RECIST v1.1 Criteria: -PD: At least a 20% increase in the sum of the diameters of target lesions with the sum demonstrating an absolute increase of at least 5 mm (0.5 cm), or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Clinical Response Criteria: -PD: increase of ≥ 25% (World Health Organization (WHO) criteria) in the sum of the products of perpendicular longest dimensions of target lesion(s) and/or the appearance of new lesions.

Time frame:
Up to approximately 65 months (treatment period + follow-up including survival follow-up)
Reported as:
Median · months
DOR by Investigator Assessment
monthsGroup 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2WGroup 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2WGroup 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3WGroup 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4WGroup 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W
DOR by Investigator AssessmentNA (30.7 to NA)41.9 (NA to NA)44.2 (25.4 to 44.2)NA (27.1 to NA)NA (29.5 to NA)
SecondaryProgression-Free Survival (PFS) by Independent Central Review

PFS was measured from start of treatment until the first date of recurrent or PD, or death due to any cause. For participants with metastatic disease, RECIST v1.1 was used to determine PD. For participants with unresectable locally advanced disease, clinical response criteria were used. RECIST v1.1 Criteria: -PD: At least a 20% increase in the sum of the diameters of target lesions with the sum demonstrating an absolute increase of at least 5 mm (0.5 cm), or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Clinical Response Criteria: -PD: increase of ≥ 25% (WHO criteria) in the sum of the products of perpendicular longest dimensions of target lesion(s) and/or the appearance of new lesions.

Time frame:
Up to approximately 65 months (treatment period + follow-up including survival follow-up)
Reported as:
Median · months
Progression-Free Survival (PFS) by Independent Central Review
monthsGroup 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2WGroup 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2WGroup 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3WGroup 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4WGroup 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W
Progression-Free Survival (PFS) by Independent Central Review18.4 (7.3 to 53.2)18.5 (11.1 to 43.8)21.7 (3.8 to 43.3)32.2 (16.6 to NA)16.6 (12.4 to 31.5)
SecondaryPFS by Investigator Assessment

PFS was measured from start of treatment until the first date of recurrent or PD, or death due to any cause. For participants with metastatic disease, RECIST v1.1 was used to determine PD. For participants with unresectable locally advanced disease, clinical response criteria were used. RECIST v1.1 Criteria: -PD: At least a 20% increase in the sum of the diameters of target lesions with the sum demonstrating an absolute increase of at least 5 mm (0.5 cm), or the appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. Clinical Response Criteria: -PD: increase of ≥ 25% (WHO criteria) in the sum of the products of perpendicular longest dimensions of target lesion(s) and/or the appearance of new lesions.

Time frame:
Up to approximately 65 months (treatment period + follow-up including survival follow-up)
Reported as:
Median · months
PFS by Investigator Assessment
monthsGroup 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2WGroup 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2WGroup 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3WGroup 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4WGroup 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W
PFS by Investigator Assessment16.6 (7.3 to NA)32.5 (17.1 to 43.8)15.2 (4.1 to 43.0)25.3 (8.2 to NA)16.5 (10.3 to 31.3)
SecondaryOverall Survival (OS)

OS was measured from start of treatment until death due to any cause.

Time frame:
Up to approximately 65 months (treatment period + follow-up including survival follow-up)
Reported as:
Median · months
Overall Survival (OS)
monthsGroup 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2WGroup 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2WGroup 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3WGroup 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4WGroup 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W
Overall Survival (OS)57.7 (29.3 to NA)NA (58.3 to NA)48.4 (29.5 to NA)NA (28.6 to NA)NA (NA to NA)
SecondaryComplete Response (CR) Rate by Independent Central Review

CR rate was defined as percentage of participants with BOR of CR. For participants with metastatic disease, RECIST v1.1 was used to determine BOR. For participants with unresectable locally advanced disease, clinical response criteria were used. RECIST v1.1 Criteria: -CR: Disappearance of all target lesions. Any pathological lymph nodes (whether target or non-target) must have reduction in short axis to \<10 mm \<1 cm. Clinical Response Criteria: -CR: All target and nontarget lesion(s) no longer visible, maintained for at least 4 weeks and no new lesions.

Time frame:
Up to 108 weeks
Reported as:
Number · percentage of participants
Complete Response (CR) Rate by Independent Central Review
percentage of participantsGroup 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2WGroup 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2WGroup 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3WGroup 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4WGroup 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W
Complete Response (CR) Rate by Independent Central Review20.3 (11.0 to 32.8)12.8 (6.3 to 22.3)19.6 (10.2 to 32.4)22.2 (12.7 to 34.5)10.8 (6.5 to 16.5)
SecondaryChange From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status (GHS) Score

EORTC QLQ-C30 is a 30-question tool used to assess the overall quality of life (QoL) in cancer participants. Items contributing to the GHS/QoL, were scored 1 ("very poor") to 7 ("excellent"). A linear transformation was applied to the raw scores so that transformed score lies between 0 to 100. A higher score indicates better global health status/functioning and a negative change from baseline indicated less improvement.

Time frame:
Baseline, Up to Cycle 12 Day 1 (Week 89)
Reported as:
Mean · score on a scale
Change From Baseline in European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) Global Health Status (GHS) Score
score on a scaleGroup 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2WGroup 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2WGroup 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3WGroup 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W
Cycle 2 Day 1 (C2D1)0.00 ± 21.4645.56 ± 18.8956.86 ± 19.6210.96 ± 17.670
C3D111.26 ± 19.2675.30 ± 21.71715.28 ± 20.6553.88 ± 15.680
C4D16.25 ± 25.0698.76 ± 19.58513.51 ± 22.5394.39 ± 15.099
C5D14.17 ± 22.3168.33 ± 21.24613.27 ± 21.4665.79 ± 18.774
C6D15.11 ± 17.4375.68 ± 28.11812.18 ± 24.5210.25 ± 21.599
C7D16.51 ± 17.6769.17 ± 22.39322.22 ± 23.6594.44 ± 18.598
C8D14.60 ± 21.08010.10 ± 21.42530.30 ± 19.8165.00 ± 25.158
C9D16.09 ± 18.9386.61 ± 26.19926.67 ± 24.4707.69 ± 20.543
C10D112.04 ± 20.84413.77 ± 26.06428.70 ± 13.8895.83 ± 22.923
C11D110.33 ± 28.18611.40 ± 22.60332.50 ± 14.40714.81 ± 19.444
C12D18.33 ± 22.38812.75 ± 24.49427.78 ± 16.6672.78 ± 26.021
SecondaryNumber of Participants With Any Treatment Emergent Adverse Event (TEAE)

An AE was defined as any untoward medical occurrence in a participant who received study drug without regard to possibility of causal relationship. Serious Adverse Events (SAEs) were defined as death, a life-threatening AE, inpatient hospitalization or prolongation of existing hospitalization, persistent or significant disability or incapacity, a congenital anomaly or birth defect, or an important medical event that jeopardized participant and required medical intervention to prevent 1 of the outcomes listed in this definition. Treatment-emergent adverse events (TEAEs) are defined as those not present at baseline or represent the exacerbation of a condition present at baseline during the on-treatment period or follow-up period. A summary of other non-serious AEs and all serious AEs, regardless of causality is located in Reported AE section.

Time frame:
Up to 108 weeks plus 105 days (5 half-lives)
Reported as:
Count of participants · Participants
Number of Participants With Any Treatment Emergent Adverse Event (TEAE)
ParticipantsGroup 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2WGroup 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2WGroup 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3WGroup 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4WGroup 5 (Participants With mCSCC and laCSCC): Cemiplimab 438 mg SC + 350 mg IV Q3WGroup 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W
Number of Participants With Any Treatment Emergent Adverse Event (TEAE)597855639163
SecondaryPeak Concentration (Cmax) of Cemiplimab
Time frame:
Up to approximately 43 months
Reported as:
Mean · milligram per liter (mg/L)
Peak Concentration (Cmax) of Cemiplimab
milligram per liter (mg/L)Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2WGroup 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2WGroup 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3WGroup 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4WGroup 5 (Participants With mCSCC and laCSCC): Cemiplimab 438 mg SC + 350 mg IV Q3WGroup 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W
After the First Dose108 ± 14784.1 ± 105132 ± 203174 ± 50.152.9 ± 18.496.3 ± 56.2
At Steady State151 ± 83.7148 ± 76.6151 ± 46.2281 ± 235174 ± 62.2142 ± 78.3
SecondaryTrough Concentration (Ctrough) of Cemiplimab
Time frame:
Up to approximately 43 months
Reported as:
Mean · mg/L
Trough Concentration (Ctrough) of Cemiplimab
mg/LGroup 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2WGroup 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2WGroup 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3WGroup 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4WGroup 5 (Participants With mCSCC and laCSCC): Cemiplimab 438 mg SC + 350 mg IV Q3WGroup 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W
After the First Dose21.5 ± 7.1226.3 ± 14.333.6 ± 32.132.1 ± 10.434.1 ± 14.123.0 ± 10.9
At Steady State69.9 ± 19.367.5 ± 29.862.7 ± 28.362.5 ± 24.165.9 ± 22.953.3 ± 20.1
SecondaryNumber of Participants With Treatment-Emergent Anti-cemiplimab Antibodies
Time frame:
Up to approximately 43 months
Reported as:
Count of participants · Participants
Number of Participants With Treatment-Emergent Anti-cemiplimab Antibodies
ParticipantsGroup 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2WGroup 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2WGroup 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3WGroup 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4WGroup 5 (Participants With mCSCC and laCSCC): Cemiplimab 438 mg SC + 350 mg IV Q3WGroup 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W
Number of Participants With Treatment-Emergent Anti-cemiplimab Antibodies100005
SecondaryORR by Independent Central Review for Participants With Evaluable PD-L1 Assays

ORR was defined as percentage of participants with BOR of CR or PR. Expression level of PD-L1 was assessed in tumor biopsy samples by immunohistochemistry (IHC). -CR: All target and nontarget lesion(s) no longer visible, maintained for at least 4 weeks and no new lesions. -PR: Decrease of at least 50% in the sum the products of perpendicular longest dimensions of target lesion(s), maintained for at least 4 weeks and no new lesions.

Time frame:
Up to 108 weeks
Reported as:
Number · percentage of participants
ORR by Independent Central Review for Participants With Evaluable PD-L1 Assays
percentage of participantsGroup 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W
PD-L1 < 1%40.5 (24.8 to 57.9)
PD-L1 >= 1%49.2 (35.9 to 62.5)
SecondaryDOR by Independent Central Review for Participants With Evaluable PD-L1 Assays

DOR was measured from the time measurement criteria are first met for CR/PR, as defined in Outcome Measure 13, whichever was recorded first, until the first date of recurrent or PD or death due to any cause in participants with BOR of CR or PR. Expression level of PD-L1 was assessed in tumor biopsy samples by IHC. -PD: increase of ≥ 25% (WHO criteria) in the sum of the products of perpendicular longest dimensions of target lesion(s) and/or the appearance of new lesions.

Time frame:
Up to approximately 65 months (treatment period + follow-up including survival follow-up)
Reported as:
Median · months
DOR by Independent Central Review for Participants With Evaluable PD-L1 Assays
monthsGroup 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W
PD-L1 < 1%31.6 (12.6 to NA)
PD-L1 >= 1%NA (NA to NA)
SecondaryPFS by Independent Central Review for Participants With Evaluable PD-L1 Assays

PFS was measured from time of enrollment until the first date of recurrent or progressive disease, or death due to any cause. Expression level of PD-L1 was assessed in tumor biopsy samples. -PD: increase of ≥ 25% (WHO criteria) in the sum of the products of perpendicular longest dimensions of target lesion(s) and/or the appearance of new lesions.

Time frame:
Up to approximately 65 months (treatment period + follow-up including survival follow-up)
Reported as:
Median · months
PFS by Independent Central Review for Participants With Evaluable PD-L1 Assays
monthsGroup 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W
PD-L1 < 1%10.7 (3.0 to 15.3)
PD-L1 >= 1%16.6 (4.0 to NA)

Adverse events

Collected over From signing of informed consent through end of study up to approximately 65 months (treatment period + follow-up including survival follow-up). Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2W27/59 (45.8%)24/59 (40.7%)56/59 (94.9%)
Group 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2W19/78 (24.4%)28/78 (35.9%)75/78 (96.2%)
Group 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3W26/56 (46.4%)23/56 (41.1%)49/56 (87.5%)
Group 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4W23/63 (36.5%)35/63 (55.6%)59/63 (93.7%)
Group 5 (Participants With mCSCC and laCSCC): Cemiplimab 438 mg SC + 350 mg IV Q3W2/9 (22.2%)2/9 (22.2%)9/9 (100%)
Group 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W59/165 (35.8%)85/165 (51.5%)147/165 (89.1%)
Group 6a (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W to 350 mg SC Q3W2/12 (16.7%)4/12 (33.3%)9/12 (75%)
Group 6b (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W to 1050 mg SC Q6W0/7 (0%)1/7 (14.3%)5/7 (71.4%)
Most frequent serious events
Showing 10 of 193
Most frequent serious events
EventGroup 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2WGroup 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2WGroup 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3WGroup 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4WGroup 5 (Participants With mCSCC and laCSCC): Cemiplimab 438 mg SC + 350 mg IV Q3WGroup 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3WGroup 6a (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W to 350 mg SC Q3WGroup 6b (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W to 1050 mg SC Q6W
ColitisGastrointestinal disorders0/590/780/560/632/90/1650/120/7
Myocardial ischaemiaCardiac disorders0/590/780/560/630/90/1650/121/7
Pneumonia aspirationInfections and infestations0/591/780/560/630/90/1651/120/7
Urinary tract infectionInfections and infestations1/591/781/560/630/91/1651/120/7
PneumonitisRespiratory, thoracic and mediastinal disorders4/594/781/561/630/90/1651/120/7
Skin lacerationInjury, poisoning and procedural complications0/590/780/561/630/91/1651/120/7
Myocardial infarctionCardiac disorders1/591/780/562/630/92/1651/120/7
HyponatraemiaMetabolism and nutrition disorders0/590/780/560/630/91/1651/120/7
CellulitisInfections and infestations4/592/781/561/630/92/1650/120/7
PneumoniaInfections and infestations2/595/780/563/630/97/1650/120/7
Most frequent other events
Showing 10 of 141
Most frequent other events
EventGroup 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2WGroup 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2WGroup 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3WGroup 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4WGroup 5 (Participants With mCSCC and laCSCC): Cemiplimab 438 mg SC + 350 mg IV Q3WGroup 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3WGroup 6a (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W to 350 mg SC Q3WGroup 6b (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3W to 1050 mg SC Q6W
Rash maculo-papularSkin and subcutaneous tissue disorders9/598/787/568/634/918/1650/120/7
FatigueGeneral disorders15/5934/7817/5614/631/944/1651/120/7
DiarrhoeaGastrointestinal disorders17/5923/7813/5617/633/939/1650/121/7
RashSkin and subcutaneous tissue disorders11/5911/7810/5612/633/911/1650/120/7
Upper respiratory tract infectionInfections and infestations6/599/785/568/633/90/1650/120/7
COVID-19Infections and infestations0/590/780/560/630/913/1654/120/7
PruritusSkin and subcutaneous tissue disorders11/5923/787/5616/631/943/1651/120/7
Actinic keratosisSkin and subcutaneous tissue disorders4/5912/787/568/630/917/1652/122/7
Blood creatinine increasedInvestigations4/595/785/567/631/90/1650/122/7
Basal cell carcinomaNeoplasms benign, malignant and unspecified (incl cysts and polyps)3/5910/783/566/630/914/1652/122/7

Baseline characteristics

The Full Analysis Set (FAS) included all enrolled participants.

Age, Customized
Age, Customized(Participants)Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2WGroup 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2WGroup 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3WGroup 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4WGroup 5 (Participants With mCSCC and laCSCC): Cemiplimab 438 mg SC + 350 mg IV Q3WGroup 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3WTotal
< 65 years1619141633098
>= 65 to < 75 years23232017443130
>= 75 years20362230294204
Sex: Female, Male
Sex: Female, Male(Participants)Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2WGroup 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2WGroup 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3WGroup 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4WGroup 5 (Participants With mCSCC and laCSCC): Cemiplimab 438 mg SC + 350 mg IV Q3WGroup 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3WTotal
Female51981043783
Male545948535130349
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2WGroup 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2WGroup 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3WGroup 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4WGroup 5 (Participants With mCSCC and laCSCC): Cemiplimab 438 mg SC + 350 mg IV Q3WGroup 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3WTotal
Hispanic or Latino1211049
Not Hispanic or Latino587555628147405
Unknown or Not Reported010011618
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Group 1 (Participants With mCSCC): Cemiplimab 3 mg/kg IV Q2WGroup 2 (Participants With laCSCC): Cemiplimab 3 mg/kg IV Q2WGroup 3 (Participants With mCSCC): Cemiplimab 350 mg IV Q3WGroup 4 (Participants With mCSCC and laCSCC): Cemiplimab 600 mg IV Q4WGroup 5 (Participants With mCSCC and laCSCC): Cemiplimab 438 mg SC + 350 mg IV Q3WGroup 6 (Participants With mCSCC and laCSCC): Cemiplimab 350 mg IV Q3WTotal
American Indian or Alaska Native0000000
Asian0222107
Native Hawaiian or Other Pacific Islander0000000
Black or African American1000001
White587554618164420
More than one race0000000
Unknown or Not Reported0100034
08

Study locations

78 sites
  • University of Arizona Cancer Center
    Phoenix, Arizona 85004, United States
  • Mayo Clinic
    Phoenix, Arizona 85054, United States
  • City of Hope Hospital
    Duarte, California 91010, United States
  • University of California, Los Angeles
    Los Angeles, California 90095, United States
  • Stanford University
    Redwood City, California 94063, United States
  • University of California, San Diego
    San Diego, California 92161, United States
  • University of Colorado, Denver
    Aurora, Colorado 80045, United States
  • Mount Sinai Comprehensive Cancer Center
    Miami Beach, Florida 33140, United States
  • H. Lee Moffitt Cancer Center
    Tampa, Florida 33612, United States
  • Northwestern University
    Chicago, Illinois 60611, United States
  • Norton Cancer Institute
    Louisville, Kentucky 40202, United States
  • Massachusetts General Hospital
    Boston, Massachusetts 02114, United States
  • Dana-Farber Cancer Institute
    Boston, Massachusetts 02130, United States
  • Barbara Ann Karmanos Cancer Institute
    Detroit, Michigan 48201, United States
  • St. Louis University
    Saint Louis, Missouri 63104, United States
  • Washington University in St. Louis
    Saint Louis, Missouri 63110, United States
  • Nebraska Methodist Hospital
    Omaha, Nebraska 68114, United States
  • New York University
    New York, New York 10016, United States
  • Memorial Sloan Kettering Cancer Center
    New York, New York 10021, United States
  • University of Rochester Medical Center
    Rochester, New York 14623, United States
  • Cleveland Clinic
    Cleveland, Ohio 44195, United States
  • St. Luke's Hematology Oncology Specialists
    Easton, Pennsylvania 18015, United States
  • Penn State Hershey Medical Center
    Hershey, Pennsylvania 17033, United States
  • Dermatology and Laser Center of Charleston
    Charleston, South Carolina 29407, United States
  • MD Anderson Cancer Center
    Houston, Texas 77030, United States
  • Huntsman Cancer Institute
    Salt Lake City, Utah 84112, United States
  • The Canberra Hospital
    Garran, Australian Capital Territory, Australia
  • Gosford Hospital
    Gosford, New South Wales, Australia
  • Royal North Shore Hospital
    St Leonards, New South Wales 2065, Australia
  • Calvary Mater Newcastle
    Waratah, New South Wales, Australia
  • Royal Brisbane & Women's Hospital
    Herston, Queensland 4029, Australia
  • Princess Alexandra Hospital
    Woolloongabba, Queensland, Australia
  • Adelaide Cancer Centre
    Kurralta Park, South Australia 5037, Australia
  • Peter MacCallum Cancer Centre
    Melbourne, Victoria 3000, Australia
  • Border Medical Oncology
    Wodonga, Victoria, Australia
  • Sir Charles Gairdner Hospital
    Nedlands, Western Australia 6009, Australia
  • Hospital de Clinicas de Porto Alegre
    Porto Alegre, Rio Grande Do Sul, Brazil
  • Liga Paranaense de Combate Ao Cancer - Hospital Erasto Gaertner
    Curitiba, Brazil
  • Fundação São Francisco Xavier-Hospital Márcio Cunha
    Ipatinga, Brazil
  • Animi
    Lages, Brazil
  • Instituto do Cancer do Estado de São Paulo ICESP
    Sao Paulo, Brazil
  • Fundação Antônio Prudente - AC Camargo Câncer Center
    São Paulo, Brazil
  • Hôpital Claude Huriez
    Lille, Nord 59037, France
  • Hopital Avicenne
    Bobigny, 93000, France
  • Hôpital Saint-André
    Bordeaux, 33000, France
  • CHU Dijon Bourgogne
    Dijon, 21079, France
  • CHRU Grenoble
    Grenoble, 38043, France
  • Hopitaux de La Timone
    Marseille, 13009, France
  • Centre Hospitalier Universitaire de Nantes
    Nantes, 44093, France
  • Hopital Cochin
    Paris, 75014, France
  • Hôpital Saint Louis
    Paris, 75475, France
  • Centre Hospitalier Lyon Sud
    Pierre Bénite, 69495, France
  • Institut Gustave Roussy
    Villejuif, 94085, France
  • Universitätsklinikum Tübingen
    Tübingen, Baden-Württemberg 72076, Germany
  • LMU Klinikum der Universität München
    Munich, Bayern 80337, Germany
  • Medizinische Hochschule Hannover
    Hannover, Niedersachsen 30625, Germany
  • Universitätsklinikum Essen
    Essen, Nordrhein-Westfalen 45147, Germany
  • Universitätsklinikum Carl Gustav Carus
    Dresden, Sachsen 01307, Germany
  • Universitatsklinikum Schleswig-Holstein
    Kiel, Schleswig-Holstein 24105, Germany
  • Charitè Campus Mitte
    Berlin, 10117, Germany
  • SRH Wald-Klinikum Gera
    Gera, 07548, Germany
  • Andreas Sygros Hosptial-University of Athen
    Athens, 16121, Greece
  • Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale
    Napoli, Campania, Italy
  • Istituto Oncologico Veneto - I.R.C.C.S.
    Padova, Veneto, Italy
  • ASST degli Spedali Civili di Brescia - Spedali Civili di Brescia
    Brescia, Italy
  • Ospedale San Salvatore
    L'Aquila, Italy
  • Istituto Europeo Di Oncologia
    Milan, Italy
  • Fondazione Policlinico Universitario A Gemelli
    Roma, Italy
  • ICO l'Hospitalet - Hospital Duran i Reynals
    L'Hospitalet de Llobregat, Barelona 08908, Spain
  • Hospital Clinic de Barcelona
    Barcelona, Cataluna 08036, Spain
  • Hospital Universitario Vall d'Hebron
    Barcelona, 08035, Spain
  • Hospital Universitario Germans Trias i Pujol
    Barcelona, 08916, Spain
  • C.H. Regional Reina Sofia - PPDS
    Cordoba, 14004, Spain
  • Hospital Universitario Ramon y Cajal
    Madrid, 28034, Spain
  • Hospital Universitario Fundacion Jimenez Diaz
    Madrid, 28040, Spain
  • Hospital Universitario 12 de Octubre
    Madrid, 28041, Spain
  • Hospital Universitario Marques de Valdecilla
    Santander, 39008, Spain
  • Fundacion Instituto Valenciano de Oncología
    Valencia, 46009, Spain
09

References and documents

Publications

  • Rischin D, Khushalani NI, Schmults CD, Guminski A, Chang ALS, Lewis KD, Lim AM, Hernandez-Aya L, Hughes BGM, Schadendorf D, Hauschild A, Thai AA, Stankevich E, Booth J, Yoo SY, Li S, Chen Z, Okoye E, Chen CI, Mastey V, Sasane M, Lowy I, Fury MG, Migden MR. Integrated analysis of a phase 2 study of cemiplimab in advanced cutaneous squamous cell carcinoma: extended follow-up of outcomes and quality of life analysis. J Immunother Cancer. 2021 Aug;9(8):e002757. doi: 10.1136/jitc-2021-002757. PubMed 34413166 ↗
  • Paccaly AJ, Migden MR, Papadopoulos KP, Yang F, Davis JD, Rippley RK, Lowy I, Fury MG, Stankevich E, Rischin D. Fixed Dose of Cemiplimab in Patients with Advanced Malignancies Based on Population Pharmacokinetic Analysis. Adv Ther. 2021 May;38(5):2365-2378. doi: 10.1007/s12325-021-01638-5. Epub 2021 Mar 25. PubMed 33768419 ↗
  • Rischin D, Migden MR, Lim AM, Schmults CD, Khushalani NI, Hughes BGM, Schadendorf D, Dunn LA, Hernandez-Aya L, Chang ALS, Modi B, Hauschild A, Ulrich C, Eigentler T, Stein B, Pavlick AC, Geiger JL, Gutzmer R, Alam M, Okoye E, Mathias M, Jankovic V, Stankevich E, Booth J, Li S, Lowy I, Fury MG, Guminski A. Phase 2 study of cemiplimab in patients with metastatic cutaneous squamous cell carcinoma: primary analysis of fixed-dosing, long-term outcome of weight-based dosing. J Immunother Cancer. 2020 Jun;8(1):e000775. doi: 10.1136/jitc-2020-000775. PubMed 32554615 ↗
  • Migden MR, Khushalani NI, Chang ALS, Lewis KD, Schmults CD, Hernandez-Aya L, Meier F, Schadendorf D, Guminski A, Hauschild A, Wong DJ, Daniels GA, Berking C, Jankovic V, Stankevich E, Booth J, Li S, Weinreich DM, Yancopoulos GD, Lowy I, Fury MG, Rischin D. Cemiplimab in locally advanced cutaneous squamous cell carcinoma: results from an open-label, phase 2, single-arm trial. Lancet Oncol. 2020 Feb;21(2):294-305. doi: 10.1016/S1470-2045(19)30728-4. Epub 2020 Jan 14. PubMed 31952975 ↗
  • Migden MR, Rischin D, Schmults CD, Guminski A, Hauschild A, Lewis KD, Chung CH, Hernandez-Aya L, Lim AM, Chang ALS, Rabinowits G, Thai AA, Dunn LA, Hughes BGM, Khushalani NI, Modi B, Schadendorf D, Gao B, Seebach F, Li S, Li J, Mathias M, Booth J, Mohan K, Stankevich E, Babiker HM, Brana I, Gil-Martin M, Homsi J, Johnson ML, Moreno V, Niu J, Owonikoko TK, Papadopoulos KP, Yancopoulos GD, Lowy I, Fury MG. PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma. N Engl J Med. 2018 Jul 26;379(4):341-351. doi: 10.1056/NEJMoa1805131. Epub 2018 Jun 4. PubMed 29863979 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Apr 2016 to primary completion in Oct 2023, 90 months.

Results were first posted in Dec 2024, 1 year 1 month after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 8, 2016
First posted
May 3, 2016
StartActual
Apr 7, 2016
Primary completionActual
Oct 18, 2023
CompletionActual
Oct 18, 2023
Results first posted
Dec 11, 2024
Last update
May 28, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 28, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02760498
Responsible party
Sponsor
First posted
May 3, 2016
Start date
Apr 7, 2016
Primary completion
Oct 18, 2023
Completion
Oct 18, 2023
Results posted
Dec 11, 2024
Last update
May 28, 2025

Study contacts

Clinical Trial Management
study director · Regeneron Pharmaceuticals

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cemiplimab

Start the discussion